2024 Trends & Predictions: Gut Health, Mood, and Market Innovation

Over the last five years, consumer-driven interest in the microbiome and its connection to gut health has grown exponentially. In 2024 alone, searches for ‘gut health’ rose by 35%, ‘microbiome’ by 31%, and ‘probiotics’ by 8%, reflecting a global shift toward understanding how these factors impact overall wellness.

(Source: Google Trends)

This trend has been evident in our work at Magnitude Biosciences. As Dr Frederique Gill, Commercial Innovation Manager, noted, “Helping customers understand the role of prebiotics and postbiotics is key. Companies that educate consumers will lead the way in this growing market.” Supporting this, searches for prebiotics have grown at twice the rate of probiotics in the past year, signaling a shift in consumer interest toward this next frontier in microbiome research. Prebiotics – compounds that support beneficial gut bacteria – are increasingly recognized for their role in optimizing gut health.

Another area gaining attention is postbiotics, which consist of the beneficial compounds produced by probiotics. However, as Frederique explained, “To differentiate in a saturated market, probiotic companies must innovate, focusing on understanding unique mechanisms of action and measurable results.”

The Microbiome-Mood Connection

Beyond gut health, the link between the microbiome and mental health is becoming a major focus. Several probiotics have been tested for their potential to treat conditions like bipolar disorder, and there is some evidence that they work yet their mechanisms remain poorly understood. Prof David Weinkove, CSO and Co-founder of Magnitude Biosciences, explained, “We have growing evidence that probiotics can improve mood, but unlocking their full potential means understanding their mechanisms of action. That will allow us to discover new probiotics that are more effective and provide confidence when using them. More research is needed.”

Dr Karthik Mohanraj, Senior Research Scientist, highlighted the role of serotonin and dopamine pathways in microbiome-related mood modulation. “Research is increasingly linking microbes to mood. Using C. elegans, we’re uncovering how they work, bringing clarity to this complex field.”

“While it’s difficult to quantify these effects in higher models, C. elegans offers a simpler system to explore how microbes may influence neurotransmitters like serotonin or dopamine, providing insights into the mechanisms underlying mood changes.” Using C. elegans, researchers can measure specific behavioural changes such as reduced movement, increased periods of stillness, and changes in proximity to food sources. These behaviours serve as quantifiable indicators of mood-related effects, offering a clear and translatable framework for studying how microbes influence mood and behaviour. This approach provides actionable insights that can bridge the gap between preclinical findings and real-world applications.


The Challenge of Differentiation

As consumer interest grows, so does the challenge for companies to stand out in a crowded and competitive market. Dr Frederique Gill emphasized, “To differentiate in a saturated market, probiotic companies must innovate, focusing on understanding unique mechanisms of action and measurable results.”

David further explored the limitations of relying solely on Colony-forming units (CFUs) in his blog, “Why CFUs Aren’t Enough: Innovating in Probiotic Research.” He highlights that CFUs don’t always correlate with product efficacy, calling on companies to prioritize measurable health outcomes and actionable insights.

Related Resources

2024 Trends & Predictions: Gut Health, Mood, and Market Innovation
2024 Trends & Predictions: Gut Health, Mood, and Market Innovation...Read More
Personal Care Magazine: Developing Efficient Probiotics in Ageing
Personal Care Magazine: Developing Efficient Probiotics in Ageing...Read More
Technology Networks: Addressing Key Limitations in Disease Models
Technology Networks Feature: Addressing Key Limitations in Disease Models...Read More
Brochure: Pharma & Biotech
Brochure: Pharma & Biotech - read and download the brochure...Read More
IBI Feature: Accelerating Drug Discovery for Diseases of Ageing: In Vivo High Throughput Screening With C. elegans
IBI Feature: Accelerating Drug Discovery for Diseases of Ageing: In Vivo High Throughput Screening W...Read More
Magnitude Biosciences Podcast Ep 1 | Dr Alex Parker: Screening probiotics to treat ALS with C. elegans
Magnitude Biosciences Podcast Ep 1 | Dr Alex Parker: Screening probiotics to treat ALS with worms...Read More
The Nematode Corner: Delaying Forgetting – How Ice and Lithium Affect Memory in C. elegans
Delaying Forgetting - How Ice and Lithium Affect Memory in C. elegans...Read More
The Nematode Corner: Toxicity Testing with C. elegans
Welcome back to “The Nematode Corner” where we explore the fascinating world of Caenorha...Read More
Brochure: Health & Nutrition
Brochure: Health & Nutrition - read and download the brochure...Read More
Probiota 2024: Exploring Probiotic Efficacy Beyond CFUs
A couple of weeks ago we attended Probiota 2024 in Milan, a global meeting to discuss the science an...Read More
Case Study: Identifying a lead candidate for slowing ageing with Gerostate Alpha
GeroState Alpha is a pharmaceutical company, based at the Buck Institute for Research on Ageing in N...Read More
Case Study: Measuring efficacy to slow ageing for drug discovery biotech Five Alarm Bio
Five Alarm Bio, a UK drug discovery startup focussing on the underlying mechanisms of ageing to deve...Read More
The Nematode Corner: Unearthing Nutraceutical Discoveries
Welcome back to “The Nematode Corner,” where we continue our journey into the extraordin...Read More
The Nematode Corner: Powering Industry Progress
Welcome to the fascinating world of C. elegans, a microscopic nematode worm that holds the key to un...Read More
Case Study – AB Biotek works with Magnitude Biosciences to accelerate probiotic development
We help our partners in the nutraceuticals & ingredients industry uncover and validate the diver...Read More
Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative new platform to test interventions for neurodegenerative disease
Lundbeck collaborates with Magnitude on innovate platform to test neurodegenerative disease interven...Read More
Tiny Worms- Experiments Fast
David Weinkove, CEO of Magnitude Biosciences joins New Matter ...Read More
Case Study: Michelin & Magnitude Biosciences
Michelin, a Fortune 500 consumer good manufacturing company and the global leader in tyre manufactur...Read More
ELRIG Drug Discovery 2021
Take a look at our Poster from ELRIG Drug Discovery 2021: Automated Monitoring of C. elegans&nb...Read More
Frontiers in Aging: Applying C. elegans to industrial drug discovery
Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery...Read More
C. elegans to accelerate industrial drug discovery and address the costs and challenges of early preclinical research
Magnitude Bioscience CEO, David Weinkove, discusses the application of C. elegans to accelerate the ...Read More
Developing a System to Quantify Efficacy of Neurodegeneration Therapeutics Using Automated Monitoring of C. elegans
Check out our poster showing how we can quantify the efficacy of neurodegeneration models...Read More
C. elegans mobility decline
This video shows an automated method to quantify that decline developed by Magnitude Biosciences whi...Read More
Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control satiety
Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control sati...Read More
Chemosensory Neurons Modulate the Response to Oomycete Recognition in Caenorhabditis elegans
The Barkoulas Lab, including our own Michael Fasseas , find an Oomycetes recognition response in&nbs...Read More
UK SPINE Recording
Our CEO, David Weinkove, discusses the use of C. elegans and how they could be used in the...Read More
Microbiome SIG Webinar Series
Our CEO, Dr. David Weinkove, explains how healthspan readouts can be used to understand mechanisms i...Read More
Automated Imaging of C. elegans for Ageing, Neurodegeneration and Behaviour
How large scale non-invasive imaging of C. elegans to enable reliable measurement of Agein...Read More
C. elegans Automated Imaging Platform
Magnitude Biosciences presentation from ELRIG online 2020 on the use of C. elegans in pre-...Read More
C. elegans Automated Imaging in Drug Discovery
De-risking drug candidates ahead of rodent studies with a non-mammalian model for ageing, neurodegen...Read More
An overview of the use of C. elegans in longevity research including the genetic manipulation of animals.
An overview of the use of C. elegans in longevity research including the genetic manipulat...Read More

Get regular updates in your inbox

Sign up to our newsletter today, to get access to the latest company and industry news